ID   CAL-27
AC   CVCL_1107
SY   Cal-27; CAL 27; Cal 27; CAL27; Cal27; Centre Antoine Lacassagne-27
DR   BTO; BTO:0000921
DR   CLO; CLO_0002178
DR   CLO; CLO_0002182
DR   EFO; EFO_0006366
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2095
DR   BCRJ; 0326
DR   BioGRID_ORCS_Cell_line; 336
DR   BioSample; SAMN03471886
DR   BioSample; SAMN10987905
DR   cancercelllines; CVCL_1107
DR   CCRID; 1101HUM-PUMC000338
DR   CCRID; 4201HUM-CCTCC00248
DR   CCTCC; GDC0248
DR   Cell_Model_Passport; SIDM00937
DR   ChEMBL-Cells; CHEMBL3308098
DR   ChEMBL-Targets; CHEMBL1075408
DR   CLS; 305029
DR   Cosmic; 686972
DR   Cosmic; 910916
DR   Cosmic; 1006469
DR   Cosmic; 1017793
DR   Cosmic; 1041674
DR   Cosmic; 1339913
DR   Cosmic; 1466800
DR   Cosmic; 1530734
DR   Cosmic; 1752762
DR   Cosmic; 2043896
DR   Cosmic; 2131842
DR   Cosmic; 2296292
DR   Cosmic-CLP; 910916
DR   DepMap; ACH-000832
DR   DSMZ; ACC-446
DR   DSMZCellDive; ACC-446
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 910916
DR   GEO; GSM422868
DR   GEO; GSM423671
DR   GEO; GSM886907
DR   GEO; GSM887972
DR   GEO; GSM1374427
DR   GEO; GSM1374428
DR   GEO; GSM1519074
DR   GEO; GSM1519075
DR   GEO; GSM1519076
DR   GEO; GSM1669648
DR   IARC_TP53; 17482
DR   IGRhCellID; CAL27%20GSE9585
DR   LiGeA; CCLE_698
DR   LINCS_LDP; LCL-1215
DR   PharmacoDB; CAL27_168_2019
DR   PRIDE; PXD002132
DR   PRIDE; PXD028810
DR   PRIDE; PXD029420
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1107
DR   PubChem_Cell_line; CVCL_1107
DR   Wikidata; Q54808394
RX   PubMed=2145926;
RX   PubMed=2440566;
RX   PubMed=3181269;
RX   PubMed=19631575;
RX   PubMed=20014447;
RX   PubMed=20164919;
RX   PubMed=21868764;
RX   PubMed=22460905;
RX   PubMed=24201445;
RX   PubMed=25275298;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25888065;
RX   PubMed=26589293;
RX   PubMed=27108184;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28476783;
RX   PubMed=29156801;
RX   PubMed=29770536;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=34977030;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 45 hours (PubMed=2145926); ~35 hours (ATCC=CRL-2095); ~20-40 hours (DSMZ=ACC-446).
CC   HLA typing: A*26:08,26:08; B*44:03,51:01; C*07:02,16:01; DQA1*01:02,02:01; DQB1*05:01,05:01; DRB1*01:03,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=25275298).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.22%; Native American=0%; East Asian, North=2.6%; East Asian, South=0%; South Asian=0%; European, North=54.66%; European, South=40.51% (PubMed=30894373).
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; DSMZ; Genomics_Center_BCF_Technion; PubMed=19631575; PubMed=21868764; PubMed=25275298; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D10S1248: 12,16
ST   D12S391: 18.3,20
ST   D13S317: 10,11
ST   D16S539: 11,12
ST   D18S51: 13
ST   D19S433: 14,15.2 (ATCC; CCRID; Genomics_Center_BCF_Technion)
ST   D19S433: 14,16 (DSMZ)
ST   D1S1656: 13,16
ST   D21S11: 28,29
ST   D22S1045: 13,16
ST   D2S1338: 23,24
ST   D2S441: 10,11.3
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D6S1043: 12
ST   D7S820: 10
ST   D8S1179: 13,15
ST   FGA: 21,25 (CCRID)
ST   FGA: 25 (ATCC; DSMZ; Genomics_Center_BCF_Technion; PubMed=19631575; PubMed=25275298; PubMed=25877200)
ST   Penta D: 9,10
ST   Penta E: 7
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C173807; Tongue adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 45
//
RX   PubMed=2145926; DOI=10.1016/0277-5379(90)90186-W;
RA   Olivier S., Formento P., Fischel J.-L., Etienne M.-C., Milano G.;
RT   "Epidermal growth factor receptor expression and suramin cytotoxicity
RT   in vitro.";
RL   Eur. J. Cancer 26:867-871(1990).
//
RX   PubMed=2440566;
RA   Gioanni J., Samson M., Zanghellini E., Mazeau C., Ettore F.,
RA   Demard F., Chauvel P., Duplay H., Schneider M., Laurent J.-C.,
RA   Lalanne C.-M.;
RT   "Characterization of a new surface epitope specific for human
RT   epithelial cells defined by a monoclonal antibody and application to
RT   tumor diagnosis.";
RL   Cancer Res. 47:4417-4424(1987).
//
RX   PubMed=3181269; DOI=10.1016/0277-5379(88)90335-5;
RA   Gioanni J., Fischel J.-L., Lambert J.-C., Demard F., Mazeau C.,
RA   Zanghellini E., Ettore F., Formento P., Chauvel P., Lalanne C.-M.,
RA   Courdi A.;
RT   "Two new human tumor cell lines derived from squamous cell carcinomas
RT   of the tongue: establishment, characterization and response to
RT   cytotoxic treatment.";
RL   Eur. J. Cancer Clin. Oncol. 24:1445-1455(1988).
//
RX   PubMed=19631575; DOI=10.1016/j.oraloncology.2009.06.001;
RA   Jiang L., Ji N., Zhou Y., Li J., Liu X.-T., Wang Z., Chen Q.-M.,
RA   Zeng X.;
RT   "CAL 27 is an oral adenosquamous carcinoma cell line.";
RL   Oral Oncol. 45:e204-e207(2009).
//
RX   PubMed=20014447; DOI=10.1002/hed.21311;
RA   Tsui I.F.L., Garnis C.;
RT   "Integrative molecular characterization of head and neck cancer cell
RT   model genomes.";
RL   Head Neck 32:1143-1160(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24201445; DOI=10.1101/gr.164806.113;
RA   Akagi K., Li J.-F., Broutian T.R., Padilla-Nash H.M., Xiao W.-H.,
RA   Jiang B., Rocco J.W., Teknos T.N., Kumar B., Wangsa D., He D., Ried T.,
RA   Symer D.E., Gillison M.L.;
RT   "Genome-wide analysis of HPV integration in human cancers reveals
RT   recurrent, focal genomic instability.";
RL   Genome Res. 24:185-199(2014).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25888065; DOI=10.1016/j.molonc.2015.03.008;
RA   Stanam A., Love-Homan L., Joseph T.S., Espinosa-Cotton M.,
RA   Simons A.L.;
RT   "Upregulated interleukin-6 expression contributes to erlotinib
RT   resistance in head and neck squamous cell carcinoma.";
RL   Mol. Oncol. 9:1371-1383(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27108184; DOI=10.1016/j.bbamcr.2016.04.019;
RA   Stojanovic N., Brozovic A., Majhen D., Bosnar M.H., Fritz G.,
RA   Osmak M., Ambriovic-Ristov A.;
RT   "Integrin alphavbeta3 expression in tongue squamous carcinoma cells
RT   Cal27 confers anticancer drug resistance through loss of
RT   pSrc(Y418).";
RL   Biochim. Biophys. Acta 1863:1969-1978(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28476783; DOI=10.21873/anticanres.11555;
RA   Hagemann J., Jacobi C., Hahn M., Schmid V., Welz C.,
RA   Schwenk-Zieger S., Stauber R.H., Baumeister P., Becker S.;
RT   "Spheroid-based 3D cell cultures enable personalized therapy testing
RT   and drug discovery in head and neck cancer.";
RL   Anticancer Res. 37:2201-2210(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=29770536; DOI=10.1111/cas.13640;
RA   Yang J., Li L., Xi Y., Sun R.-M., Wang H., Ren Y.-X., Zhao L.-F.,
RA   Wang X.-L., Li X.-Y.;
RT   "Combination of IFITM1 knockdown and radiotherapy inhibits the growth
RT   of oral cancer.";
RL   Cancer Sci. 109:3115-3128(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=34977030; DOI=10.3389/fcell.2021.786758;
RA   Tadijan A., Humphries J.D., Samarzija I., Stojanovic N., Zha J.-Z.,
RA   Culjak K., Tomic M., Paradzik M., Nestic D., Kang H., Humphries M.J.,
RA   Ambriovic-Ristov A.;
RT   "The tongue squamous carcinoma cell line Cal27 primarily employs
RT   integrin alpha6beta4-containing type II hemidesmosomes for adhesion
RT   which contribute to anticancer drug sensitivity.";
RL   Front. Cell Dev. Biol. 9:786758.1-786758.17(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//